Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed: 18,156
Companies: 1,062
Drugs tracked: 3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources

Quick answer

Placebo to Ibuzatrelvir film-coated tablet, PF-07817883 Tablet

Placebo to Ponsegromab (PF-06946860), CALCIUM LEVOFOLINATE PENTAHYDRATE, Ponsegromab (PF-06946860)

Placebo to Remdesivir - Saline, Remdesivir, PF-07817883 Tablet, Placebo to Ibuzatrelvir

Placebo to match Apremilast film-coated tablets, deucravacitinib, Placebo to match deucravacitinib tablet, Otezla 10mg, 20mg, 30 mg film-coated tablets

Placebo to match ritlecitinib 50 mg, Ritlecitinib tosilate, Ritlecitinib, Placebo to match ritlecitinib 30 mg

RIMEGEPANT SULFATE, Placebo to rimegepant sulfate

Rimegepant Placebo, VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, 25 mg oral lyophilisate, 50 mg oral lyophilisate

Ritlecitinib tosilate, Placebo to match ritlecitinib 50 mg, Ritlecitinib, Placebo to match ritlecitinib 30 mg

Ritlecitinib tosilate, Ritlecitinib Tosilate

Sasanlimab

TALAZOPARIB, TALAZOPARIB, TALAZOPARIB, Xtandi - 40 mg soft capsules, TALAZOPARIB

TOFACITINIB, TOFACITINIB, Tofacitinib citrate

VYDURA 75 mg oral lyophilisate, 35 mg oral lyophilisate, Placebo for 75 mg Rimegepant, Placebo for 50 mg rimegepant, 50 mg oral lyophilisate, Placebo for 35 mg rimegepant, Placebo for 25 mg Rimegepant, 25 mg oral lyophilisate

VYDURA 75 mg oral lyophilisate, matching placebo for 75 mg oral lyophilisate

XALKORI 250 mg hard capsules, XALKORI 200 mg hard capsules, Repotrectinib (TPX-0005), Repotrectinib (TPX-0005)

XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, XELJANZ 1 mg/mL oral solution, Tofacitinib citrate, Tofacitinib citrate, XELJANZ 1 mg/mL oral solution

Xtandi - 40 mg soft capsules, PF-06821497, PF-06821497, Tablet to match placebo for pf-06821497 125mg, Tablet to match placebo for pf-06821497 250mg

Xtandi - 40 mg soft capsules, Xtandi - 40 mg soft capsules, TALAZOPARIB, Xtandi 40 mg soft capsules, TALAZOPARIB, Xtandi - 40 mg soft capsules, Talazoparib placebo

Zelvina 15 mg hard capsules, Zelvina 5 mg hard capsules, ELRANATAMAB, Zelvina 10 mg hard capsules, Privigen 100 mg/ml solution for infusion

deucravacitinib, Placebo to match BMS 986165 tablet

deucravacitinib, Placebo to match deucravacitinib 6mg tablets in bottle, oral use, deucravacitinib, Placebo to match deucravacitinib 2mg minitablets in sachet, oral use

deucravacitinib, Placebo to match deucravacitinib tablet

Frequently asked questions